During the past decade, Behavioral Pharmacology Research Unit conducted 35 clinical trials. In the 10-year time frame, 35 clinical trials started and 17 clinical trials were completed, i.e. on average, 48.6% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 4 clinical trials were completed. i.e. 16.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Behavioral Pharmacology Research Unit" #1 sponsor was "Johns Hopkins University" with 60 trials, followed by "National Institute on Drug Abuse (NIDA)" with 11 trials sponsored, "Titan Pharmaceuticals" with 4 trials sponsored, "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials sponsored and "Pain Therapeutics" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Behavioral Pharmacology Research Unit" #1 collaborator was "National Institute on Drug Abuse (NIDA)" with 33 trials as a collaborator, "Johns Hopkins University" with 4 trials as a collaborator, "Substance Abuse and Mental Health Services Administration (SAMHSA)" with 4 trials as a collaborator, "Heffter Research Institute" with 2 trials as a collaborator and "RTI International" with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Behavioral Pharmacology Research Unit" are "Opioid-Related Disorders" (13 trials), "Healthy" (7 trials), "Opioid Dependence" (7 trials), "Cannabis" (4 trials) and "Anxiety" (3 trials). Many other conditions were trialed in "Behavioral Pharmacology Research Unit" in a lesser frequency.

Most popular intervention types in "Behavioral Pharmacology Research Unit" are "Drug" (66 trials), "Behavioral" (14 trials), "Device" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (18 trials), "Buprenorphine" (7 trials), "Psilocybin" (5 trials), "Buprenorphine/naloxone" (4 trials) and "Cannabis" (4 trials). Other intervention names were less common.

The vast majority of trials in "Behavioral Pharmacology Research Unit" are 74 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are 22 active trials in "Behavioral Pharmacology Research Unit". 2 are not yet recruiting, 16 are recruiting, 3 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 48 completed trials in Behavioral Pharmacology Research Unit, undefined suspended trials, and 6 terminated clinical trials to date.

Out of the total trials that were conducted in Behavioral Pharmacology Research Unit, 37 "Phase 1" clinical trials were conducted, 27 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 13 trials that are defined as “Not Applicable".